Type 1 Diabetes Clinical Trial
Official title:
Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol
Manually suspending an insulin pump at the beginning of aerobic exercise reduces the risk of
exercise-associated hypoglycemia (low blood sugar) in patients with type 1 diabetes (T1D).
However, since patients with T1D often do not make exercise-related adjustments to their
insulin regimen, our group has developed an algorithm to initiate pump suspension in a
user-independent manner upon projecting exercise-associated hypoglycemia. The current study
seeks to test the efficacy of this algorithm by asking users to participate in a sports camp
while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate
monitor (to detect exercise), which will communicate electronically to a pump shutoff
algorithm. On one of the days the algorithm will be used, while on the other day their normal
insulin rate will continue for comparative purposes.
The investigators hypothesize that the use of an accelerometer-augmented computer algorithm
for insulin pump suspension during exercise will result in significantly fewer episodes of
hypoglycemia (both during exercise and in post-exercise monitoring) than in exercise without
a pump suspension algorithm.
Regular aerobic exercise confers a plethora of health benefits to all individuals and is
considered an essential component of the management of type 1 diabetes (T1D) [1]. However, in
contrast to non-diabetic subjects - in whom the increased muscle energy requirement during
exercise leads to suppression of endogenous insulin secretion - patients with T1D are
dependent upon exogenous insulin and are thus at risk for exercise-associated hypoglycemia
[1]. Exercise-associated hypoglycemia is the most frequently reported adverse event related
to exercise in diabetes [2] and hypoglycemia can occur during exercise or several hours
afterwards [3,4]. Although previous research has shown that pre-meal dose reduction of
subcutaneous insulin can be effective at decreasing the incidence of exercise-associated
hypoglycemia [5], patients with T1D often do not perform such adjustments [6,7].
In contrast to subcutaneous insulin injections, which are reliant upon the patient or
caretaker to determine dosage, the insulin pump provides a unique opportunity to avoid
hypoglycemia via user-independent, computer-based algorithms for determining insulin
delivery. Previous research conducted here at Stanford has demonstrated that algorithms based
on continuous glucose monitor (CGM) data can prevent hypoglycemia in the sedentary setting by
inducing insulin pump suspension [8-10]. In addition, a study of children and adolescents
conducted at Stanford (as a center in the DirecNet group) demonstrated that suspending an
insulin pump at the beginning of a period of moderate aerobic exercise reduces the risk of
hypoglycemia during that exercise period and subsequently overnight [11]. Thus, by utilizing
exercise-detecting accelerometers and an algorithm to initiate pump suspension during
exercise, it is likely possible that people with diabetes could avoid exercise-associated
hypoglycemia even if they failed to manually alter their pump settings. However, to date, no
published studies have utilized accelerometer-derived data in an insulin pump suspension
algorithm during exercise.
Accelerometers are light-weight motion-sensing devices that can be worn to provide
information about the intensity and duration of physical activity [12]. They are small,
inexpensive, and could easily be incorporated into current sensors and "patch" pumps. They
can also be used independently or combined with a heart rate monitor (HRM) [13], although
most commercially available HRMs currently require a chest strap that can be uncomfortable to
wear. Previous studies evaluating the effect of physical activity on insulin sensitivity have
utilized accelerometers (worn on a belt at the small of the back, the right side of the trunk
in the mid-axillary line, or the left side of the chest) with and without HRMs for activity
recognition during subjects' everyday lives. These data were used to classify activity as
sedentary, light, moderate, or vigorous based on acceleration signal counts measured over
one-minute intervals [13-17]. One study investigated four different accelerometers in a
clinical research setting and found each to be very accurate in assessing the intensity of
physical activity, regardless of subjects' body habitus [18]. Thus, these devices can provide
a reliable means by which the onset, duration, and intensity of exercise can be recognized
and reported in real-time to the other components of an artificial pancreas. When combined
with CGM and insulin delivery data, this exercise information is a valuable tool in designing
an algorithm to decrease or stop insulin delivery in order to decrease the risk of
exercise-associated hypoglycemia.
In the first phase of this study (in press), 22 subjects with type 1 diabetes went about
their everyday lives while wearing an insulin pump, CGM, and accelerometer/heart rate
monitor. After the monitoring period, the devices were downloaded and the data were used to
augment an existing predictive low glucose suspend (PLGS) algorithm to incorporate activity.
In a computer simulator, the PLGS algorithm reduced hypoglycemia by 64%, compared to 73% and
76% reductions for the accelerometer-augmented and HRM-augmented algorithms, respectively.
In the next phase of this study, we seek to test the newly developed algorithm in a real-life
setting in the form of a structured sports (soccer) camp to further see if modifications to
the algorithm are required.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 |